Advertisement
U.S. markets open in 8 hours 13 minutes

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.14-0.14 (-0.50%)
At close: 04:00PM EDT
28.38 +0.24 (+0.85%)
After hours: 05:24PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Megaphone Top

Megaphone Top

Previous Close28.28
Open28.28
Bid29.40 x 1100
Ask30.14 x 1100
Day's Range27.21 - 28.36
52 Week Range20.67 - 42.48
Volume1,273,612
Avg. Volume1,662,316
Market Cap3.486B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.77
Earnings DateApr 30, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARWR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arrowhead Pharmaceuticals, Inc.
    ARWR: Lowering target price to $30.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • InvestorPlace

    The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024

    After closing out 2023 with a 15.1% gain, the Russell 2000 looks even better this year in the new year. In fact, since Jan. 2, the index is up about 4% year to date, and could push even higher, taking some of the most undervalued Russell 2000 stocks along for the ride. According to Goldman Sachs, the Russell 2000 Index could return about 9% in the first six months of the year, and about 15% in the next 12 months. All thanks to low valuations, and an improving economic outlook. As noted by Invest

  • GuruFocus.com

    Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares

    Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing.

  • Business Wire

    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

    PASADENA, Calif., March 08, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy.